Yet another unresolved issue for the serrated precursor-CRC field, and potentially one of greater significance for colorectal cancer screening recommendations in the general population in the future, is whether a potentially significant fraction of human CRCs arise from benign serrated lesions that are currently presumed to be of low malignant potential, such as HPPs in the distal colon and rectum, with or without BRAFT1799Amutations, or proximal colon serrated lesions with KRAS mutations. The gene discussed is KRAS; the disease is colorectal cancer.